Comparison of budesonide Turbuhaler with budesonide aqua in the <font color="blue">treatment_1</font> <font color="blue">of_1</font> <font color="blue">seasonal_2</font> <font color="blue">allergic_2</font> <font color="blue">rhinitis_2</font> <font color="blue">._2</font> Rhinocort Study Group . 
<br>
<br> OBJECTIVE To compare the effect of budesonide Turbuhaler 400 microg / day with budesonide aqua 256 microg / day in the <font color="blue">treatment_1</font> <font color="blue">of_1</font> <font color="blue">seasonal_1</font> <font color="blue">allergic_1</font> <font color="blue">rhinitis_1</font> <font color="blue">(_1</font> <font color="blue">SAR_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> Secondarily to ascertain <font color="blue">patients_1</font> <font color="blue">'_1</font> <font color="blue">preferences_1</font> for the two nasal devices and to assess quality of life . 
<br> DESIGN Randomized , multicentre , double - blind , double- dummy , parallel groups study . 
<br> SETTING <font color="blue">Private_2</font> <font color="blue">practices_2</font> <font color="blue">and_2</font> <font color="blue">hospital_2</font> <font color="blue">clinics_2</font> <font color="blue">in_2</font> <font color="blue">Ontario_2</font> <font color="blue">,_2</font> <font color="blue">Quebec_2</font> <font color="blue">and_2</font> <font color="blue">Manitoba_2</font> <font color="blue">._2</font> 
<br> POPULATION <font color="blue">Two_5</font> <font color="blue">hundred_5</font> <font color="blue">and_5</font> <font color="blue">eighty_5</font> <font color="blue">-_5</font> <font color="blue">four_5</font> <font color="blue">out_5</font> <font color="blue">-_5</font> <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">SAR_5</font> <font color="blue">,_5</font> <font color="blue">who_4</font> <font color="blue">were_4</font> <font color="blue">symptomatic_4</font> <font color="blue">during_4</font> <font color="blue">the_4</font> <font color="blue">ragweed_4</font> <font color="blue">season_4</font> <font color="blue">,_4</font> <font color="blue">volunteered_2</font> <font color="blue">for_2</font> <font color="blue">enrolment_2</font> <font color="blue">(_2</font> <font color="blue">243_2</font> <font color="blue">randomized_2</font> <font color="blue">)_2</font> <font color="blue">._2</font> <font color="blue">
<br>_1</font> RESULTS Mean daily nasal symptom scores were significantly reduced with treatment . There were no statistically significant changes from baseline for eye symptoms . Most patients ( more than 80% ) achieved substantial control of their symptoms with budesonide . The most common nasal and non - nasal adverse events for both groups were epistaxis and headache . Turbuhaler was easier to use and more convenient to carry , had less of an unpleasant taste , and caused less nasal irritation than the aqua spray . More than twice as many patients preferred Turbuhaler to the aqua spray ( 69% versus 31% ) . Improvement in quality of life from baseline to clinic visits was statistically significant in both groups . 
<br> CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally safe and efficacious in the <font color="blue">treatment_1</font> <font color="blue">of_1</font> <font color="blue">SAR_1</font> <font color="blue">._1</font> Patients preferred the budesonide powder formulation delivered via Turbuhaler two to one over the aqua formulation .